Recent Updates
Recently added Catalysts
XLO Positive Sentiment

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Monday, February 24, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xilio Therapeutics, a biotechnology firm specializing in tumor-activated immuno-oncology therapies, announced that CEO Ren Russo will speak at the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 3, 2025, at 9:50 am EST. A live webcast will be available for viewing on the company's website, and an archived version will be accessible for a month after the event.
Price reaction · baseline $13.02 (2025-02-21 close) · clean, no other XLO news in the window
day 0 close
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xilio Therapeutics is actively engaged in a significant healthcare conference.
  • Participation demonstrates the company's commitment to transparency with investors.
  • The live webcast allows broader access to information about the company's developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
21.2%
average across 4 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
XTX501
Phase 1 · Metastatic NSCLC - Non-Small Cell Lung Cancer

Full Press Release Details

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50 am EST.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact

Frequently Asked Questions

When will Xilio Therapeutics' fireside chat occur?

The fireside chat is scheduled for March 3, 2025, at 9:50 am EST.

Who will participate in the fireside chat?

René Russo, Pharm.D., will participate in the fireside chat.

How can I access the live webcast?

The live webcast is available on the Xilio Therapeutics website.

Will there be a replay of the webcast?

Yes, a replay will be available for 30 days post-presentation.

What is Xilio Therapeutics focused on?

Xilio Therapeutics develops tumor-activated immuno-oncology therapies for cancer.

ShareAdd on Google
Tags: XLO Viatris Investor Conferences Healthcare Xilio Therapeutics TD Cowen healthcare conference cancer therapies immuno-oncology
Last updated: Feb 24, 2025

Biotech snapshot

Cash runway
$136M liquidity · $6M/mo burn
~22 mo
Low dilution risk
Lead asset
XTX501Phase 1
Metastatic NSCLC - Non-Small Cell Lung Cancer →

Catalyst track record

+66%
best trade around XLO's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for XLO.

See every catalyst's timing & PoA →